A citation-based method for searching scientific literature

Brian Zambrowicz, Ike Ogbaa, Kenny Frazier, Phillip Banks, Anne Turnage, Joel Freiman, Kristi A Boehm, Dennis Ruff, David Powell, Arthur Sands. Clin Ther 2013
Times Cited: 40







List of co-cited articles
329 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Phlorizin: a review.
Joel R L Ehrenkranz, Norman G Lewis, C Ronald Kahn, Jesse Roth. Diabetes Metab. Res. Rev. 2005
410
12

The role of SGLT1 and GLUT2 in intestinal glucose transport and sensing.
Pia V Röder, Kerstin E Geillinger, Tamara S Zietek, Bernard Thorens, Hermann Koepsell, Hannelore Daniel. PLoS ONE 2014
138
12

Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2.
Gwen Tolhurst, Helen Heffron, Yu Shan Lam, Helen E Parker, Abdella M Habib, Eleftheria Diakogiannaki, Jennifer Cameron, Johannes Grosse, Frank Reimann, Fiona M Gribble. Diabetes 2012
746
12

Use of Adjuvant Pharmacotherapy in Type 1 Diabetes: International Comparison of 49,996 Individuals in the Prospective Diabetes Follow-up and T1D Exchange Registries.
Sarah K Lyons, Julia M Hermann, Kellee M Miller, Sabine E Hofer, Nicole C Foster, Birgit M Rami-Merhar, Grazia Aleppo, Jochen Seufert, Linda A DiMeglio, Thomas Danne,[...]. Diabetes Care 2017
21
23

Effects of Sotagliflozin Added to Insulin in Type 1 Diabetes.
Satish K Garg, Paul Strumph. N. Engl. J. Med. 2018
11
45

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N. Engl. J. Med. 2017
12

Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats.
L Rossetti, G I Shulman, W Zawalich, R A DeFronzo. J. Clin. Invest. 1987
215
10

SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects.
Ele Ferrannini, Anna Solini. Nat Rev Endocrinol 2012
217
10

Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.
James F List, Vincent Woo, Enrique Morales, Weihua Tang, Fred T Fiedorek. Diabetes Care 2009
392
10

SGLT2 inhibition--a novel strategy for diabetes treatment.
Edward C Chao, Robert R Henry. Nat Rev Drug Discov 2010
329
10

Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial.
Bruce Neal, Vlado Perkovic, Dick de Zeeuw, Kenneth W Mahaffey, Greg Fulcher, Peter Stein, Mehul Desai, Wayne Shaw, Joel Jiang, Frank Vercruysse,[...]. Am. Heart J. 2013
211
10

SGLT inhibitors in management of diabetes.
Abd A Tahrani, Anthony H Barnett, Clifford J Bailey. Lancet Diabetes Endocrinol 2013
132
10

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise.
K Stenlöf, W T Cefalu, K-A Kim, M Alba, K Usiskin, C Tong, W Canovatchel, G Meininger. Diabetes Obes Metab 2013
368
10

Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial.
Peter Stein, Jolene K Berg, Linda Morrow, David Polidori, Eunice Artis, Sarah Rusch, Nicole Vaccaro, Damayanthi Devineni. Metab. Clin. Exp. 2014
35
11

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
Benjamin M Scirica, Deepak L Bhatt, Eugene Braunwald, P Gabriel Steg, Jaime Davidson, Boaz Hirshberg, Peter Ohman, Robert Frederich, Stephen D Wiviott, Elaine B Hoffman,[...]. N. Engl. J. Med. 2013
10

Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
William B White, Christopher P Cannon, Simon R Heller, Steven E Nissen, Richard M Bergenstal, George L Bakris, Alfonso T Perez, Penny R Fleck, Cyrus R Mehta, Stuart Kupfer,[...]. N. Engl. J. Med. 2013
10

Expression cloning and cDNA sequencing of the Na+/glucose co-transporter.
M A Hediger, M J Coady, T S Ikeda, E M Wright. Nature 1987
612
10

Activation of sodium-glucose cotransporter 1 ameliorates hyperglycemia by mediating incretin secretion in mice.
Ryuichi Moriya, Takashi Shirakura, Junko Ito, Satoshi Mashiko, Toru Seo. Am. J. Physiol. Endocrinol. Metab. 2009
105
10

Molecular basis for glucose-galactose malabsorption.
Ernest M Wright, Eric Turk, Martin G Martin. Cell Biochem. Biophys. 2002
65
10

Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion.
Caroline Bonner, Julie Kerr-Conte, Valéry Gmyr, Gurvan Queniat, Ericka Moerman, Julien Thévenet, Cédric Beaucamps, Nathalie Delalleau, Iuliana Popescu, Willy J Malaisse,[...]. Nat. Med. 2015
306
10

Predominant role of active versus facilitative glucose transport for glucagon-like peptide-1 secretion.
H E Parker, A Adriaenssens, G Rogers, P Richards, H Koepsell, F Reimann, F M Gribble. Diabetologia 2012
115
10

Accelerated intestinal glucose absorption in morbidly obese humans: relationship to glucose transporters, incretin hormones, and glycemia.
Nam Q Nguyen, Tamara L Debreceni, Jenna E Bambrick, Bridgette Chia, Judith Wishart, Adam M Deane, Chris K Rayner, Michael Horowitz, Richard L Young. J. Clin. Endocrinol. Metab. 2015
43
10

Sodium-Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport: From Bench to Bedside.
Sunder Mudaliar, David Polidori, Brian Zambrowicz, Robert R Henry. Diabetes Care 2015
98
10

Sotagliflozin as a potential treatment for type 2 diabetes mellitus.
Bertrand Cariou, Bernard Charbonnel. Expert Opin Investig Drugs 2015
18
22

Intestinal SGLT1 in metabolic health and disease.
Anders Lehmann, Pamela J Hornby. Am. J. Physiol. Gastrointest. Liver Physiol. 2016
24
16

Type 1 diabetes in older adults: Comparing treatments and chronic complications in the United States T1D Exchange and the German/Austrian DPV registries.
Ruth S Weinstock, Ingrid Schütz-Fuhrmann, Crystal G Connor, Julia M Hermann, David M Maahs, Morten Schütt, Shivani Agarwal, Sabine E Hofer, Roy W Beck, Reinhard W Holl. Diabetes Res. Clin. Pract. 2016
18
22


HbA1c and Hypoglycemia Reductions at 24 and 52 Weeks With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: The European inTandem2 Study.
Thomas Danne, Bertrand Cariou, Phillip Banks, Michael Brandle, Helmut Brath, Edward Franek, Jake A Kushner, Pablo Lapuerta, Darren K McGuire, Anne L Peters,[...]. Diabetes Care 2018
61
10

Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study.
John B Buse, Satish K Garg, Julio Rosenstock, Timothy S Bailey, Phillip Banks, Bruce W Bode, Thomas Danne, Jake A Kushner, Wendy S Lane, Pablo Lapuerta,[...]. Diabetes Care 2018
74
10



T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes.
A Oku, K Ueta, K Arakawa, T Ishihara, M Nawano, Y Kuronuma, M Matsumoto, A Saito, K Tsujihara, M Anai,[...]. Diabetes 1999
142
7


Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.
Julio Rosenstock, Naresh Aggarwal, David Polidori, Yue Zhao, Deborah Arbit, Keith Usiskin, George Capuano, William Canovatchel. Diabetes Care 2012
282
7

Biology of incretins: GLP-1 and GIP.
Laurie L Baggio, Daniel J Drucker. Gastroenterology 2007
7

A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes.
E Ferrannini, L Seman, E Seewaldt-Becker, S Hantel, S Pinnetti, H J Woerle. Diabetes Obes Metab 2013
120
7


Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial.
Michael Roden, Jianping Weng, Jens Eilbracht, Bruno Delafont, Gabriel Kim, Hans J Woerle, Uli C Broedl. Lancet Diabetes Endocrinol 2013
257
7


Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis.
Despoina Vasilakou, Thomas Karagiannis, Eleni Athanasiadou, Maria Mainou, Aris Liakos, Eleni Bekiari, Maria Sarigianni, David R Matthews, Apostolos Tsapas. Ann. Intern. Med. 2013
423
7


Ipragliflozin: first global approval.
Raewyn M Poole, Rosselle T Dungo. Drugs 2014
58
7

Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2.
Sreeneeranj Kasichayanula, Xiaoni Liu, Frank Lacreta, Steven C Griffen, David W Boulton. Clin Pharmacokinet 2014
97
7

Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial.
Guntram Schernthaner, Jorge L Gross, Julio Rosenstock, Michael Guarisco, Min Fu, Jacqueline Yee, Masato Kawaguchi, William Canovatchel, Gary Meininger. Diabetes Care 2013
318
7

Canagliflozin , an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus.
Elizabeth M Lamos, Lisa M Younk, Stephen N Davis. Expert Opin Drug Metab Toxicol 2013
28
10

Luseogliflozin: first global approval.
Anthony Markham, Shelley Elkinson. Drugs 2014
38
7


A novel glucose-sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line.
Fiona M Gribble, Leanne Williams, Anna K Simpson, Frank Reimann. Diabetes 2003
234
7

Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1.
Hyeung-Jin Jang, Zaza Kokrashvili, Michael J Theodorakis, Olga D Carlson, Byung-Joon Kim, Jie Zhou, Hyeon Ho Kim, Xiangru Xu, Sic L Chan, Magdalena Juhaszova,[...]. Proc. Natl. Acad. Sci. U.S.A. 2007
561
7

Glucose sensing in L cells: a primary cell study.
Frank Reimann, Abdella M Habib, Gwen Tolhurst, Helen E Parker, Gareth J Rogers, Fiona M Gribble. Cell Metab. 2008
448
7


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.